Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 1990
Dose-dependent pharmacokinetics of MK-417, a potent carbonic anhydrase inhibitor, in rabbits following single and multiple dosesJ H Lin, I W Chen, E H Ulm, et al.Journal of Medicinal Chemistry|September 1, 1975
4-Trifluoromethylimidazoles and 5-(4-pyridyl)-1,2,4-triazoles, new classes of xanthine oxidase inhibitorsJ J Baldwin, P A Kasinger, F C Novello, et al.Clinical Pharmacology and Therapeutics|March 1, 1977
The disposition of sulindacD E Duggan, L E Hare, C A Ditzler, et al.Clinical Pharmacology and Therapeutics|February 1, 1983
Enterohepatic circulation of sulindac and metabolitesC A Dujovne, A Pitterman, W C Vincek, et al.Journal of Medicinal Chemistry|September 1, 1977
2-pyridylimidazoles as inhibitors of xanthine oxidaseJ J Baldwin, P K Lumma, F C Novello, et al.Journal of Pharmacokinetics and Biopharmaceutics|December 1, 1978
Effects of concomitant aspirin administration on the pharmacokinetics of indomethacin in manK C Kwan, G O Breault, R L Davis, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 1, 1993
Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and humanR A Halpin, E H Ulm, A E Till, et al.Biopharmaceutics & Drug Disposition|October 1, 1983
Biliary secretion of sulindac and metabolites in manM R Dobrinska, D E Furst, T Spiegel, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 1989
The physiological disposition of lovastatinD E Duggan, I W Chen, W F Bayne, et al.Journal of Pharmaceutical Sciences|August 1, 1985
Bioanalysis and disposition of alpha-fluoromethylhistidine, a new histidine decarboxylase inhibitorT F August, D G Musson, S S Hwang, et al.Pageof 5